The "Regenerative Medicine Collaboration and Licensing Deals 2016-2024" report has been added to ResearchAndMarkets.com's offering.



Regenerative Medicine Collaboration and Licensing Deals provides a comprehensive understanding and unprecedented access to the regenerative medicine deals entered into by the world's leading biopharma companies. This report contains a comprehensive listing of 1771 regenerative medicine deals announced since 2016 including financial terms where available including links to online deal records of actual regenerative medicine partnering deals as disclosed by the deal parties.

Fully revised and updated, the report provides details of regenerative medicine deals from 2016 to 2024. The report provides a detailed understanding and analysis of how and why companies enter regenerative medicine deals. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes. The report includes collaboration, development, research and licensing deals.



The report also includes numerous table and figures that illustrate the trends and activities in regenerative medicine deal making since 2016. In addition, a comprehensive deal directory is provided organized by company A-Z, deal type and therapeutic target. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.



The initial chapters of this report provide an orientation of regenerative medicine dealmaking.



Chapter 1 provides an introduction to the report.



Chapter 2 provides an overview of the trends in regenerative medicine dealmaking since 2016.



Chapter 3 provides an overview of the leading regenerative medicine deals since 2016. Deals are listed by headline value.



Chapter 4 provides a comprehensive listing of the top 25 most active companies in regenerative medicine dealmaking with a brief summary followed by a comprehensive listing of regenerative medicine deals, as well as contract documents available in the public domain.



Chapter 5 provides a comprehensive and detailed review of regenerative medicine deals signed and announced since Jan 2016, where a contract document is available in the public domain.



Chapter 6 provides a comprehensive and detailed review of regenerative medicine partnering deals signed and announced since Jan 2016. The chapter is organized by specific regenerative medicine technology type in focus.



Key Benefits

• Understand deal trends since 2016
• Browse regenerative medicine collaboration and licensing deals
• Benchmark analysis - identify market value of transactions
• Financials terms - upfront, milestone, royalties
• Directory of deals by company A-Z, deal type and therapy area
• Leading deals by value
• Most active dealmakers
• Identify assets and deal terms for each transaction
• Access contract documents - insights into deal structures
• Due diligence - assess suitability of your proposed deal terms for partner companies
• Save hundreds of hours of research time

Report Scope

• Trends in regenerative medicine dealmaking in the biopharma industry
• Directory of regenerative medicine deal records covering pharmaceutical and biotechnology
• The leading regenerative medicine deals by value
• Most active regenerative medicine licensing dealmakers

Analyzing contract agreements allows due diligence of:

• What are the precise rights granted or optioned?
• What is actually granted by the agreement to the partner company?
• What exclusivity is granted?
• What is the payment structure for the deal?
• How are sales and payments audited?
• What is the deal term?
• How are the key terms of the agreement defined?
• How are IPRs handled and owned?
• Who is responsible for commercialization?
• Who is responsible for development, supply, and manufacture?
• How is confidentiality and publication managed?
• How are disputes to be resolved?
• Under what conditions can the deal be terminated?
• What happens when there is a change of ownership?
• What sublicensing and subcontracting provisions have been agreed?
• Which boilerplate clauses does the company insist upon?
• Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?
• Which jurisdiction does the company insist upon for agreement law?

Key Topics Covered:



Chapter 1 - Introduction



Chapter 2 - Trends in regenerative medicine dealmaking

2.1. Introduction

2.2. Regenerative medicine deals over the years

2.3. Most active regenerative medicine dealmakers

2.4. Regenerative medicine deals by deal type

2.5. Regenerative medicine deals by therapy area

2.6. Regenerative medicine deals by industry sector

2.7. Deal terms for regenerative medicine deals

2.7.1 Regenerative medicine deals headline values

2.7.2 Regenerative medicine deal upfront payments

2.7.3 Regenerative medicine deal milestone payments

2.7.4 Regenerative medicine royalty rates



Chapter 3 - Leading regenerative medicine deals

3.1. Introduction

3.2. Top regenerative medicine deals by value



Chapter 4 - Most active regenerative medicine dealmakers

4.1. Introduction

4.2. Most active regenerative medicine dealmakers

4.3. Most active regenerative medicine deals company profiles



Chapter 5 - Regenerative medicine contracts dealmaking directory

5.1. Introduction

5.2. Regenerative medicine contracts dealmaking directory



Chapter 6 - Regenerative medicine dealmaking by technology type



Deal directory

• Deal directory - Regenerative medicine deals by company A-Z
• Deal directory - Regenerative medicine deals by deal type
• Deal directory - Regenerative medicine deals by therapy area

For more information about this report visit https://www.researchandmarkets.com/r/j7nfjk

About ResearchAndMarkets.com

ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240704577974/en/